DX-104 Advances as a Next-Generation OMV Vaccine Candidate
DX-104, a next-generation gOMV vaccine candidate for MenB, is planned for trials in China and Australia. The process scaled to 100 L, reached 98% purity, and is projected to yield over 1 million doses per batch.